154 related articles for article (PubMed ID: 25536640)
1. Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C.
Martínez-Macías RF; Cordero-Pérez P; Juárez-Rodríguez OA; Chen-López CY; Martínez-Carrillo FM; Alarcón-Galván G; Mercado-Hernández R; Muñoz-Espinosa LE
Ann Hepatol; 2015; 14(1):36-45. PubMed ID: 25536640
[TBL] [Abstract][Full Text] [Related]
2. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
3. Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis.
Dultz G; Seelhof M; Herrmann E; Welker MW; Friedrich-Rust M; Teuber G; Kronenberger B; von Wagner M; Vermehren J; Sarrazin C; Zeuzem S; Hofmann WP
PLoS One; 2013; 8(8):e71262. PubMed ID: 23936497
[TBL] [Abstract][Full Text] [Related]
4. Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
Lens S; Rincón D; García-Retortillo M; Albillos A; Calleja JL; Bañares R; Abraldes JG; Bosch J; Sanchez-Tapias JM; Forns X; García-Pagán JC
Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1846-1853.e1. PubMed ID: 25912838
[TBL] [Abstract][Full Text] [Related]
5. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
6. Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
Morgan TR; Ghany MG; Kim HY; Snow KK; Shiffman ML; De Santo JL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Dienstag JL; Morishima C; Lindsay KL; Lok AS;
Hepatology; 2010 Sep; 52(3):833-44. PubMed ID: 20564351
[TBL] [Abstract][Full Text] [Related]
7. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C.
Labarga P; Fernández-Montero JV; de Mendoza C; Barreiro P; Soriano V
Antivir Ther; 2015; 20(1):65-72. PubMed ID: 25105286
[TBL] [Abstract][Full Text] [Related]
9. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.
Veldt BJ; Heathcote EJ; Wedemeyer H; Reichen J; Hofmann WP; Zeuzem S; Manns MP; Hansen BE; Schalm SW; Janssen HL
Ann Intern Med; 2007 Nov; 147(10):677-84. PubMed ID: 18025443
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis.
Di Martino V; Crouzet J; Hillon P; Thévenot T; Minello A; Monnet E
J Viral Hepat; 2011 Jul; 18(7):493-505. PubMed ID: 21692956
[TBL] [Abstract][Full Text] [Related]
13. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
14. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
15. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study.
Wedemeyer H; Reimer J; Sandow P; Hueppe D; Lutz T; Gruengreiff K; Goelz J; Christensen S; Pfeiffer-Vornkahl H; Alshuth U; Manns MP
Liver Int; 2017 Oct; 37(10):1468-1475. PubMed ID: 28247572
[TBL] [Abstract][Full Text] [Related]
17. Summaries for patients. Sustained virologic response in hepatitis C.
Ann Intern Med; 2007 Nov; 147(10):I47. PubMed ID: 18025441
[No Abstract] [Full Text] [Related]
18. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA; Rivero-Juárez A; López-Cortés LF; Girón-González JA; Téllez F; de los Santos-Gil I; Macías J; Merino D; Márquez M; Ríos-Villegas MJ; Gea I; Merchante N; Rivero A; Torres-Cornejo A; Pineda JA;
Clin Infect Dis; 2013 Jun; 56(11):1646-53. PubMed ID: 23429381
[TBL] [Abstract][Full Text] [Related]
19. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
20. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
